Easty D L, Carter C
Trans Ophthalmol Soc U K (1962). 1979 Apr;99(1):126-33.
Laboratory studies show that systemic immunity protects the corneal epithelium against herpes simplex virus (HSV) infection, this protection probably being humoral in origin. It can be shown that hyperimmune gammaglobulin (HGG) has a similar protective action when instilled up to 2 hours after the induction of the ulcerative disease. Topical steroids enhance proliferation of HSV in epithelial disease, but at low dilutions there is some evidence that resistance is enhanced. Human studies of systemic immunity show that there is a response in cell-mediated immunity (CMI) after primary and recurrent ulcerative disease. Certain patients with severe stromal keratitis have evidence of CMI deficiency compared to controls or to patients with epithelial disease. To prevent virus spread into the stroma, early use of antiviral therapy is essential. Stromal disease does not only represent a hypersensitivity phenomenon, but is probably associated with virus proliferation in the keratocytes. Potent steroid medication will theoretically deplete immuno-protective responses, and promote further virus proliferation. Therefore the lowest possible concentrations achieving a clinical response should be employed.
实验室研究表明,全身免疫可保护角膜上皮免受单纯疱疹病毒(HSV)感染,这种保护作用可能源于体液免疫。研究表明,在溃疡性疾病诱发后2小时内滴注超免疫球蛋白(HGG)具有类似的保护作用。局部使用类固醇会促进上皮疾病中HSV的增殖,但在低浓度时,有证据表明抵抗力会增强。对全身免疫的人体研究表明,原发性和复发性溃疡性疾病后细胞介导免疫(CMI)会产生反应。与对照组或上皮疾病患者相比,某些严重基质性角膜炎患者有CMI缺陷的证据。为防止病毒扩散到基质中,早期使用抗病毒治疗至关重要。基质疾病不仅代表一种超敏反应现象,而且可能与角膜细胞中的病毒增殖有关。强效类固醇药物理论上会消耗免疫保护反应,并促进病毒进一步增殖。因此,应采用能达到临床反应的最低可能浓度。